-
Je něco špatně v tomto záznamu ?
Post-transplant cyclophosphamide in one-antigen mismatched unrelated donor transplantation versus haploidentical transplantation in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the EBMT
G. Battipaglia, JE. Galimard, M. Labopin, AM. Raiola, D. Blaise, A. Ruggeri, Y. Koc, Z. Gülbas, A. Vitek, S. Sica, JL. Diez-Martin, L. Castagna, B. Bruno, M. Rovira, I. Moiseev, M. Martino, G. Grillo, MC. Araujo, CE. Bulabois, S. Nguyen, G....
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články
NLK
Free Medical Journals
od 1997 do Před 1 rokem
Freely Accessible Science Journals
od 1997 do Před 1 rokem
ProQuest Central
od 2000-01-01 do Před 1 rokem
Open Access Digital Library
od 1997-01-01
Health & Medicine (ProQuest)
od 2000-01-01 do Před 1 rokem
- MeSH
- akutní myeloidní leukemie * terapie MeSH
- cyklofosfamid farmakologie terapeutické užití MeSH
- haploidentická transplantace MeSH
- lidé MeSH
- nemoc štěpu proti hostiteli * MeSH
- nepříbuzný dárce MeSH
- příprava pacienta k transplantaci MeSH
- retrospektivní studie MeSH
- transplantace hematopoetických kmenových buněk * MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
Whether to choose Haploidentical (Haplo) or one-antigen mismatched unrelated donor (1Ag-MMUD) hematopoietic cell transplantation (HCT) with post-transplant cyclophosphamide (PTCy) remains an unanswered question. We compared PTCy- Haplo-HCT to PTCy-1Ag-MMUD-HCT for acute myeloid leukemia (AML) in complete remission (three groups: 1Ag-MMUD using peripheral blood (1Ag-MMUD-PB; n = 155); Haplo using bone marrow (Haplo-BM; n = 647) or peripheral blood (Haplo-PB; n = 949)). Haplo-BM and Haplo-PB had a higher non-relapse mortality (NRM) compared to 1Ag-MMUD-PB (HR 2.28, 95% CI 1.23-4.24, p < 0.01; HR 2.65, 95% CI 1.46-4.81, p < 0.01, respectively). Haplo groups experienced a lower leukemia-free survival (LFS) compared to 1Ag-MMUD-PB (Haplo-BM: HR 1.51, 95% CI 1.06-2.14, p = 0.02; Haplo-PB: 1.47, 95% CI 1.05-2.05, p = 0.02); overall survival (OS) was also lower in Haplo-HCT (Haplo-BM: HR 1.50, 95% CI 1.02-2.21, p = 0.04; Haplo-PB: HR 1.51, 95% CI 1.05-2.19, p = 0.03). No differences were observed for graft-versus-host/relapse-free survival (GRFS) and relapse incidence (RI). Haplo-BM was associated with a lower risk of grade III-IV acute graft-versus-host disease (GVHD) (HR 0.44, 95% CI 0.24-0.81; p < 0.01), while no statistical differences were observed between groups for grade II-IV aGVHD and for cGVHD. Use of PTCy in 1Ag-MMUD-HCT is a valid alternative to consider when using alternative donors. Larger analysis of 1Ag-MMUD versus Haplo-HCT are warranted.
Alberts Cellular Therapy Netcare Pretoria East Hospital Pretoria South Africa
Anadolu Medical Center Hospital Bone Marrow Transplantation Department Kocaeli Turkey
ASST GRANDE OSPEDALE METROPOLITANO NIGUARDA Hematology Department Milano Italy
Centro de Investigación del Cáncer IBMCC Salamanca Spain
Chaim Sheba Medical Center Tel Hashomer Israel
CHU Bordeaux Hôpital Haut leveque Pessac France
CHU Grenoble Alpes Université Grenoble Alpes Service d'Hématologie Grenoble France
Department of Clinical Medicine and Surgery Federico 2 University of Naples Naples Italy
EBMT Statistical Unit Paris France
Federico 2 University of Naples Hematology Department Naples Italy
Florence Nightingale Sisli Hospital Hematopoietic SCT Unit Istanbul Turkey
Fondazione Policlinico A Gemelli IRCCS Roma Italy
Goethe Universitaet Medizinische Klinik 2 Hämatologie Medizinische Onkologie Frankfurt Main Germany
Hematology Department Complejo Asistencial Universitario de Salamanca IBSAL
Hematology Department Hôpital Saint Antoine Service d'Hématologie Thérapie Cellulaire Paris France
Hematology Service Institute of Hematology and Blood Transfusion Prague Czech Republic
Hopital St Louis Dept of Hematology BMT Paris France
Hospital Clinic BMT Unit Dept of Hematology IDIBAPS Institut Josep Carreras Barcelona Spain
Hospital U Marqués de Valdecilla Servicio de Hematología Hemoterapia Santander Spain
Imperial College Department of Haematology Hammersmith Hospital London United Kingdom
IRCCS Humanitas Research Hospital Rozzano Milan Italy
Istituto di Ematologia Università Cattolica del Sacro Cuore Roma Italy
Klinikum Grosshadern Med Klinik 3 Munich GermanyKlinikum Grosshadern Med Klinik 3 Munich Germany
Medicana International Istanbul Turkey
Ospedale San Raffaele s r l Haematology and BMT Milano Italy
R M Gorbacheva Research Institute Pavlov University Saint Petersburg Russian Federation
Sorbonne Universités UPMC Univ Paris 06 INSERM Centre de Recherche Saint Antoine Paris France
SSCVD Trapianto di Cellule Staminali AOU Città della Salute e della Scienza di Torino Turin Italy
Universite Paris 4 Hopital la Pitié Salpêtrière Hematologie Clinique Paris France
University Medical Center Groningen University of Groningen Groningen The Netherlands
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22018913
- 003
- CZ-PrNML
- 005
- 20240528150903.0
- 007
- ta
- 008
- 220720s2022 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41409-022-01577-x $2 doi
- 035 __
- $a (PubMed)35079140
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Battipaglia, Giorgia $u Federico II University of Naples, Hematology Department, Naples, Italy. giorgia.battipaglia@unina.it $u Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy. giorgia.battipaglia@unina.it $1 https://orcid.org/0000000206953879
- 245 10
- $a Post-transplant cyclophosphamide in one-antigen mismatched unrelated donor transplantation versus haploidentical transplantation in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the EBMT / $c G. Battipaglia, JE. Galimard, M. Labopin, AM. Raiola, D. Blaise, A. Ruggeri, Y. Koc, Z. Gülbas, A. Vitek, S. Sica, JL. Diez-Martin, L. Castagna, B. Bruno, M. Rovira, I. Moiseev, M. Martino, G. Grillo, MC. Araujo, CE. Bulabois, S. Nguyen, G. Socié, M. Arat, J. Pavlu, J. Tischer, H. Martin, LL. Corral, G. Choi, E. Forcade, A. McDonald, F. Pane, A. Bazarbachi, F. Ciceri, A. Nagler, M. Mohty
- 520 9_
- $a Whether to choose Haploidentical (Haplo) or one-antigen mismatched unrelated donor (1Ag-MMUD) hematopoietic cell transplantation (HCT) with post-transplant cyclophosphamide (PTCy) remains an unanswered question. We compared PTCy- Haplo-HCT to PTCy-1Ag-MMUD-HCT for acute myeloid leukemia (AML) in complete remission (three groups: 1Ag-MMUD using peripheral blood (1Ag-MMUD-PB; n = 155); Haplo using bone marrow (Haplo-BM; n = 647) or peripheral blood (Haplo-PB; n = 949)). Haplo-BM and Haplo-PB had a higher non-relapse mortality (NRM) compared to 1Ag-MMUD-PB (HR 2.28, 95% CI 1.23-4.24, p < 0.01; HR 2.65, 95% CI 1.46-4.81, p < 0.01, respectively). Haplo groups experienced a lower leukemia-free survival (LFS) compared to 1Ag-MMUD-PB (Haplo-BM: HR 1.51, 95% CI 1.06-2.14, p = 0.02; Haplo-PB: 1.47, 95% CI 1.05-2.05, p = 0.02); overall survival (OS) was also lower in Haplo-HCT (Haplo-BM: HR 1.50, 95% CI 1.02-2.21, p = 0.04; Haplo-PB: HR 1.51, 95% CI 1.05-2.19, p = 0.03). No differences were observed for graft-versus-host/relapse-free survival (GRFS) and relapse incidence (RI). Haplo-BM was associated with a lower risk of grade III-IV acute graft-versus-host disease (GVHD) (HR 0.44, 95% CI 0.24-0.81; p < 0.01), while no statistical differences were observed between groups for grade II-IV aGVHD and for cGVHD. Use of PTCy in 1Ag-MMUD-HCT is a valid alternative to consider when using alternative donors. Larger analysis of 1Ag-MMUD versus Haplo-HCT are warranted.
- 650 _2
- $a cyklofosfamid $x farmakologie $x terapeutické užití $7 D003520
- 650 12
- $a nemoc štěpu proti hostiteli $7 D006086
- 650 12
- $a transplantace hematopoetických kmenových buněk $7 D018380
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a akutní myeloidní leukemie $x terapie $7 D015470
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a příprava pacienta k transplantaci $7 D019172
- 650 _2
- $a haploidentická transplantace $7 D000075442
- 650 _2
- $a nepříbuzný dárce $7 D061349
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Galimard, Jacques-Emmanuel $u EBMT Statistical Unit, Paris, France $1 https://orcid.org/0000000191024427
- 700 1_
- $a Labopin, Myriam $u EBMT Statistical Unit, Paris, France $u Hematology Department, Hôpital Saint Antoine, Service d'Hématologie Thérapie Cellulaire, Paris, France $u Sorbonne Universités, UPMC Univ Paris 06, INSERM, Centre de Recherche Saint-Antoine (CRSA), Paris, France $1 https://orcid.org/0000000345144748
- 700 1_
- $a Raiola, Anna Maria $u UOC Ematologia e Trapianto di Midollo Osseo, IRCCS Ospedale Policlinico San Martino Genova, Genova, Italy
- 700 1_
- $a Blaise, Didier $u Programme de Transplantation & Therapie Cellulaire, Institut Paoli-Calmettes, Aix Marseille Univ, CNRS, INSERM, CRCM, Marseille, France $1 https://orcid.org/0000000256849447
- 700 1_
- $a Ruggeri, Annalisa $u Ospedale San Raffaele s.r.l., Haematology and BMT, Milano, Italy $1 https://orcid.org/0000000272612765
- 700 1_
- $a Koc, Yener $u Medicana International, Istanbul, Turkey
- 700 1_
- $a Gülbas, Zafer $u Anadolu Medical Center Hospital, Bone Marrow Transplantation Department, Kocaeli, Turkey
- 700 1_
- $a Vitek, Antonin $u Hematology Service, Institute of Hematology and Blood Transfusion, Prague, Czech Republic
- 700 1_
- $a Sica, Simona $u Fondazione Policlinico A. Gemelli IRCCS, Roma, Italy; Istituto di Ematologia, Università Cattolica del Sacro Cuore, Roma, Italy
- 700 1_
- $a Diez-Martin, Jose Luiz $u Hematology department, Hospital General Universitario Gregorio Marañon, Instituto de Investigación Sanitaria Gregorio Marañon, Universidad Complutense Medicina, Madrid, Spain
- 700 1_
- $a Castagna, Luca $u IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy
- 700 1_
- $a Bruno, Benedetto $u SSCVD Trapianto di Cellule Staminali, AOU Città della Salute e della Scienza di Torino, Turin, Italy
- 700 1_
- $a Rovira, Montserrat $u Hospital Clinic, BMT Unit, Dept. of Hematology, IDIBAPS, Institut Josep Carreras, Barcelona, Spain
- 700 1_
- $a Moiseev, Ivan $u R.M. Gorbacheva Research Institute, Pavlov University, Saint Petersburg, Russian Federation $1 https://orcid.org/0000000243320114
- 700 1_
- $a Martino, Massimo $u Division of Stem Cell Transplantation and Cellular Therapies, Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli", Reggio Calabria, Italy $1 https://orcid.org/000000023987419X
- 700 1_
- $a Grillo, Giovanni $u ASST GRANDE OSPEDALE METROPOLITANO NIGUARDA, Hematology Department, Milano, Italy
- 700 1_
- $a Araujo, Mercedes Colorado $u Hospital U. Marqués de Valdecilla, Servicio de Hematología-Hemoterapia, Santander, Spain
- 700 1_
- $a Bulabois, Claude Eric $u CHU Grenoble Alpes - Université Grenoble Alpes, Service d'Hématologie, Grenoble, France
- 700 1_
- $a Nguyen, Stéphanie $u Universite Paris IV, Hopital la Pitié-Salpêtrière, Hematologie Clinique, Paris, France
- 700 1_
- $a Socié, Gerard $u Hopital St. Louis, Dept. of Hematology - BMT, Paris, France $1 https://orcid.org/0000000221147533
- 700 1_
- $a Arat, Mutlu $u Florence Nightingale Sisli Hospital, Hematopoietic SCT Unit, Istanbul, Turkey $1 https://orcid.org/0000000320398557
- 700 1_
- $a Pavlu, Jiri $u Imperial College, Department of Haematology, Hammersmith Hospital, London, United Kingdom
- 700 1_
- $a Tischer, Johanna $u Klinikum Grosshadern, Med. Klinik III, Munich, GermanyKlinikum Grosshadern, Med. Klinik III, Munich, Germany
- 700 1_
- $a Martin, Hans $u Goethe-Universitaet, Medizinische Klinik II, Hämatologie, Medizinische Onkologie, Frankfurt-Main, Germany
- 700 1_
- $a Corral, Lucia Lopez $u Hematology Department, Complejo Asistencial Universitario de Salamanca-IBSAL; Centro de Investigación del Cáncer-IBMCC, Salamanca, Spain
- 700 1_
- $a Choi, Goda $u University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
- 700 1_
- $a Forcade, Edouard $u CHU Bordeaux, Hôpital Haut-leveque, Pessac, France $1 https://orcid.org/0000000288732868
- 700 1_
- $a McDonald, Andrew $u Alberts Cellular Therapy, Netcare Pretoria East Hospital, Pretoria, South Africa
- 700 1_
- $a Pane, Fabrizio $u Federico II University of Naples, Hematology Department, Naples, Italy $u Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy
- 700 1_
- $a Bazarbachi, Ali $u Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon $1 https://orcid.org/0000000271714997
- 700 1_
- $a Ciceri, Fabio $u Ospedale San Raffaele s.r.l., Haematology and BMT, Milano, Italy $1 https://orcid.org/0000000308730123
- 700 1_
- $a Nagler, Arnon $u EBMT Statistical Unit, Paris, France $u Chaim Sheba Medical Center, Tel-Hashomer, Israel $1 https://orcid.org/0000000207631265
- 700 1_
- $a Mohty, Mohamad $u EBMT Statistical Unit, Paris, France $u Hematology Department, Hôpital Saint Antoine, Service d'Hématologie Thérapie Cellulaire, Paris, France $u Sorbonne Universités, UPMC Univ Paris 06, INSERM, Centre de Recherche Saint-Antoine (CRSA), Paris, France $7 xx0317729
- 773 0_
- $w MED00000834 $t Bone marrow transplantation $x 1476-5365 $g Roč. 57, č. 4 (2022), s. 562-571
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35079140 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220720 $b ABA008
- 991 __
- $a 20240528150859 $b ABA008
- 999 __
- $a ok $b bmc $g 1822484 $s 1170156
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 57 $c 4 $d 562-571 $e 20220125 $i 1476-5365 $m Bone marrow transplantation $n Bone Marrow Transplant $x MED00000834
- LZP __
- $a Pubmed-20220720
